# ICU Medical Inc: Form 10-Q for the period ended Mar 31, 2016

- Company: [ICU Medical Inc](/companies/icui.md) (CIK 883984)
- Form: 10-Q
- Filed: 2016-05-10
- Accepted by EDGAR: May 10, 2016, 17:14 ET
- Period: 2016-03-31
- Accession: 0000883984-16-000063
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/883984/000088398416000063/icui0331201610-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/883984/000088398416000063/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-01-01 to 2016-03-31 | $89.9m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-01-01 to 2016-03-31 | $40.6m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2016-01-01 to 2016-03-31 | $49.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2016-01-01 to 2016-03-31 | $3.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-01-01 to 2016-03-31 | $22.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-01-01 to 2016-03-31 | $23.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2016-01-01 to 2016-03-31 | $8.2m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2016-01-01 to 2016-03-31 | $0.96 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-01-01 to 2016-03-31 | $0.99 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-01-01 to 2016-03-31 | 16,556,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2016-01-01 to 2016-03-31 | $14.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2016-01-01 to 2016-03-31 | $4.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2016-01-01 to 2016-03-31 | $16.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2016-03-31 | $347.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-03-31 | $515.4m | us-gaap:AssetsCurrent |
| Total assets | at 2016-03-31 | $636.0m | us-gaap:Assets |
| Current liabilities | at 2016-03-31 | $34.0m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2016-03-31 | $595.9m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 30,244 characters.

When used in this report, the terms “we,” “us,” and “our,” refer to ICU Medical, Inc. and its subsidiaries included in our condensed consolidated financial statements unless context requires otherwise.

### Business Overview

We are a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, critical care and oncology applications. Our product line includes needlefree connection devices, custom infusion sets, closed system transfer devices ("CSTD") for the handling of hazardous drugs, advanced sensor catheters, closed blood sampling systems and innovative hemodynamic monitoring systems.

Our products are used in acute care hospitals and ambulatory clinics in more than 60 countries throughout the world. The following table summarizes our total worldwide revenue by domestic and international markets by amount and as a percentage of total revenue (in millions, except percentages):

|  | Three months ended March 31, 2016 $% of Revenue |  | 2015 $% of Revenue |  | Fiscal year ended 2015 $% of Revenue |  | 2014 $% of Revenue |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Domestic | $61.7 | 69% | $57.7 | 71% | $241.8 | 71% | $212.6 | 69% |
| International | 28.2 | 31% | 23.8 | 29% | 99.9 | 29% | 96.7 | 31% |
| Total Revenue | $89.9 | 100% | $81.5 | 100% | $341.7 | 100% | $309.3 | 100% |

We categorize our products into three main market segments: Infusion Therapy, Critical Care and Oncology. Our primary products include:

#### Infusion Therapy

- Needlefree connector products
- MicroClave® and MicroClave Clear®
- Neutron®
- NanoClave®
- Clave®
- SwabCap®
- Custom infusion sets
- Tego® needlefree hemodialysis connector

#### Critical Care

- Hemodynamic monitoring systems
- Closed Blood Sampling and Conservation Systems
- Other Critical Care Products and Accessories

#### Oncology

- ChemoLock® CSTD and components
- ChemoClave® CSTD and components
- Diana™ hazardous drug compounding system

The following table sets forth, for the periods indicated, total revenues by product line as a percentage of total revenues:

| Product line | Three months ended March 31, 2016 | 2015 | Fiscal year ended 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Infusion therapy | 72.0% | 72% | 72% | 70% |
| Critical care | 15.0% | 17% | 16% | 18% |
| Oncology | 13.0% | 11% | 12% | 12% |
|  | 100.0% | 100% | 100% | 100% |

We currently sell our products through direct channels, which include distributors and the end users of our products and as an original equipment manufacturer ("OEM") supplier. Most of our independent distributors handle the full line of our products.

Our largest customer is Hospira, Inc. a subsidiary of Pfizer, to which we distribute our products as an OEM supplier. Pfizer accounted for 34%, 36% and 36% of our worldwide revenues in the first three months of 2016 and each of the years ended 2015 and 2014, respectively. We began this relationship in 1995 with Hospira, which was acquired by Pfizer in September 2015. Our related agreements extend through December 2018. Our agreements with Pfizer provide them with conditional rights to distribute certain of our Clave and other products to certain categories of customers both in the United States ("U.S.") and foreign countries. Depending on the product and category of customer, these rights may be exclusive or nonexclusive. Pfizer purchases Clave products both as finished goods end-products for distribution to healthcare providers and in bulk for assembly into Pfizer infusion disposable products. The MicroClave, MicroClave Clear, ChemoClave CSTD and pre-pierced connector products are purchased and packaged separately as finished good end products. We also serve as the exclusive manufacturer for certain custom intravenous products that are sold by a subsidiary of Pfizer. These products are promoted under the name SetSource. Our relationship with Pfizer has been and will continue to be important for our growth. We expect revenues from infusion therapy products and new product sales to Pfizer to remain a significant percentage of our revenues. An adverse change in our relationship with Pfizer, or a deterioration of Pfizer’s position in the market, could have an adverse effect on us.

We believe that as healthcare providers continue to either consolidate or join major buying organizations, the success of our products will depend, in part, on our ability, either independently or through strategic relationships such as our Pfizer relationship, to secure long-term contracts with large healthcare providers and major buying organizations. As a result of this marketing and distribution strategy we derive most of our revenues from a relatively small number of distributors and manufacturers. The loss of a strategic relationship with a customer or a decline in demand for manufacturing customers' products could have a material adverse effect on our operating results.

We believe that achievement of our growth objectives worldwide will require increased efforts by us in sales and marketing and product acquisition and development; however, there is no assurance that we will be successful in implementing our growth strategy. Product development or acquisition efforts may not succeed, and even if we do develop or acquire additional products, there is no assurance that we will achieve profitable sales of such products. Increased expenditures for sales and marketing and product acquisition and development may not yield desired results when expected, or at all. While we have taken steps to control these risks, there are certain risks that may be outside of our control, and there is no assurance that steps we have taken will succeed.

### Seasonality/Quarterly Results

The healthcare business in the U.S. is subject to quarterly fluctuations due to frequency of illness during the seasons, elective procedures, and over the last few years, the economy. In Europe, the healthcare business generally slows down in the summer months due to vacations resulting in fewer elective surgeries. In addition, we can experience fluctuations in net sales as a result of variations in the ordering patterns of our largest customers, which may be driven more by production scheduling and their inventory levels, and less by seasonality. Our expenses often do not fluctuate in the same manner as net sales, which may cause fluctuations in operating income that are disproportionate to fluctuations in our revenue.

### Quarter-to-Quarter Comparisons

We present income statement data in Part I, Item 1 - Financial Statements. The following table shows, for the three months ended March 31, 2016 and 2015, respectively, and the year ended December 31, 2015, the percentages of each income statement caption in relation to total revenues:

|  | Three months ended March 31, 2016 | 2015 | Fiscal year ended 2015 |
| --- | ---: | ---: | ---: |
| Total revenues | 100% | 100% | 100% |
| Gross margin | 55% | 52% | 53% |
| Selling, general and administrative expenses | 24% | 25% | 24% |
| Research and development expenses | 4% | 5% | 5% |
| Restructuring and strategic transaction expenses | —% | —% | 2% |
| Legal settlements | —% | 9% | 1% |
| Impairment of assets held for sale | —% | —% | 1% |
| Total operating expenses | 28% | 39% | 33% |
| Income from operations | 27% | 13% | 20% |
| Other income | —% | 1% | —% |
| Income before income taxes | 27% | 14% | 20% |
| Income taxes | 9% | 2% | 7% |
| Net income | 18% | 12% | 13% |

### Quarter Ended March 31, 2016 Compared to the Quarter Ended March 31, 2015

### Infusion Therapy Revenue

The following table summarizes our total infusion therapy revenue by direct and OEM distribution channels (in millions):

|  | Quarter ended March 31, 2016 | 2015 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Direct | $35.5 | $31.1 | $4.4 | 14.1% |
| OEM | 29.5 | 27.7 | 1.8 | 6.5% |
| Total Infusion Therapy Revenue | $65.0 | $58.8 | $6.2 | 10.5% |

Direct infusion therapy sales increased in the first quarter of 2016, as compared to the same period in the prior year, primarily due to sales of our SwabCap product-line, which was acquired through an acquisition in October 2015. Partially offsetting this increase was a decrease in sales of our Tego needlefree hemodialysis connector primarily due to a one-time inventory stocking adjustment at a U.S. distributor combined with a temporary manufacturing constraint in the quarter.

OEM infusion therapy sales increased in the first quarter of 2016, as compared to the same period in the prior year, primarily a result of the sales of our OEM SwabCap product.

### Critical Care Revenue

The following table summarizes our total critical care revenue by direct and OEM distribution channels (in millions):

|  | Quarter ended March 31, 2016 | 2015 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Direct | $13.0 | $13.6 | $(0.6) | (4.4)% |
| OEM | — | 0.1 | (0.1) | (100.0)% |
| Total Critical Care Revenue | $13.0 | $13.7 | $(0.7) | (5.1)% |

Direct critical care sales decreased in the first quarter of 2016, as compared to the same period in the prior year, primarily due to a decline in U.S. sales of both our hemodynamic monitoring and our closed blood sampling and conservation system products. The decreases were primarily due to a manufacturing issue that was rectified during the last month of the quarter.

### Oncology Revenue

The following table summarizes our total oncology revenue by direct and OEM distribution channels (in millions):

|  | Quarter ended March 31, 2016 | 2015 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Direct | $8.4 | $6.0 | $2.4 | 40.0% |
| OEM | 3.3 | 2.7 | 0.6 | 22.2% |
| Total Oncology Revenue | $11.7 | $8.7 | $3.0 | 34.5% |

Direct oncology sales increased in the first quarter of 2016, as compared to the same period in the prior year, primarily due to increased sales in the U.S. These increases were a result of new customer sales and an increase in sales to existing customers of our ChemoLock and ChemoClave product.

OEM oncology sales marginally increased during the first quarter of 2016, as compared to the prior year comparable period due to an increase in international orders of our ChemoClave product.

### Gross margins

For the first quarter of 2016 and 2015 gross margins were 55% and 52%, respectively. The increase in gross margin was primarily due to favorable foreign exchange rates on our operations expenses due to the decline in the Mexican Peso and due to favorable product mix.

### Selling, general and administrative (“SG&A”) expenses

SG&A expenses were $22.0 million, or 24% of revenues, in the first quarter of 2016, compared with $20.2 million, or 25% of revenues, in the first quarter of 2015. The $1.8 million increase was primarily due to an increase of $1.9 million in compensation and $0.8 million in higher outside services, partially offset by $0.5 million in lower legal expenses and $0.4 million in lower medical device excise taxes. The increase in compensation is in part due to filling positions that were open during 2015, additional employees retained as part of the acquired SwabCap product line, the general hiring and recruitment of new employees and increases in stock-based compensation issued to attract these employees. The increase in outside services was due to fees incurred in the first quarter of 2016 related to a transitional services agreement associated with the October 2015 acquisition of EXC Holding Corp. Legal fees in the first quarter of 2015 were higher than those in the first quarter of 2016 primarily due to a lawsuit with Hospira that settled in April 2015. Also, the medical device excise tax expense in the current period was eliminated as Congress temporarily suspended this tax for the 2016-2017 two-year period.

### Research and development (“R&D”)

R&D expenses were $3.3 million, or 4% of revenue, in the first quarter of 2016 compared to $4.3 million, or 5% of revenue, in the first quarter of 2015. The $1.0 million decrease was primarily due to lower R&D project expenses related to our CogentTM 2-in1 hemodymanic monitoring system, which is currently pending USFDA 510(k) clearance.

### Legal settlement charges

Legal settlement charges were $7.1 million, or 9% of revenues, in the first quarter of 2015. On April 2, 2015, an arbitrator ruled on a breach of contract claim between us and Hospira, awarding Hospira $8.2 million Canadian dollars ($6.5 million U.S. dollars). The arbitrator also ruled that we pay 75% of Hospira's legal fees and expenses, which were $0.7 million dollars. We have fully paid the above mentioned legal fees and expenses.

### Other income

Other income was $0.1 million in the first quarter of 2016 and $0.5 million the first quarter of 2015.

### Income taxes

Income taxes were accrued at an estimated effective tax rate of 34% in the first quarter of 2016 and 16% in the first quarter of 2015. The 2015 rate significantly differed from the statutory corporate rate of 35% principally because of the effect of foreign and state income taxes, tax credits, deductions for domestic production activities, discrete tax items related to the conclusion of federal tax examinations and changes in estimates of tax reserves.

### Liquidity and Capital Resources

During the first three months of 2016, our cash, cash equivalents and investment securities increased by $6.3 million from $377.4 million at December 31, 2015 to $383.7 million at March 31, 2016.

### Cash Flows from Operating Activities

Our cash provided by operations for the first three months of 2016 was $14.8 million. Net income plus adjustments for non-cash net expenses contributed $25.1 million to cash provided by operations, and cash used by changes in operating assets and liabilities was $10.3 million. The changes in operating assets and liabilities included a $8.0 million decrease in accrued liabilities, a $4.9 million increase in inventories, a $3.5 million increase in prepaid expenses and other assets, and a $1.4 million decrease in accounts payable, partially offset by $4.9 million in net changes to income taxes and deferred income taxes and a $2.6 million decrease in accounts receivable. The decrease in accrued liabilities was primarily due to the pay-out of fiscal year 2015 accrued bonuses in February of 2016. The increase in inventories was primarily due to building finished good safety stock, to support better customer deliveries, raw materials related to our Slovakia plant closure, and related transfer to our Mexico plant, and inventory associated with the acquired SwabCap product-line. The increase in prepaid expenses and other assets was primarily due to amounts owed by employees for the exercise of their stock options, the decrease in accounts payable was a result of timing, the net changes in income taxes was a result of the timing of payments for cash tax purposes, which includes true-ups for 2015 overpayment and 2016 estimated taxes and the decrease in accounts receivable was due to increased collections on past due accounts.

Our cash provided by operations for the first three months of 2015 was $13.3 million. Net income plus adjustments for non-cash net expenses contributed $18.1 million to cash provided by operations, which was partially offset by $4.8 million in net cash used as a result of changes in operating assets and liabilities. The largest change in operating assets and liabilities was a $5.0 million increase in accounts receivable primarily due to higher revenue in the first quarter of 2015 compared to the fourth quarter of 2014.

### Cash Flows from Investing Activities

The following table summarizes the changes in our investing cash flows (in thousands):

| Investing Cash Flows: | Three Months Ended March 31, 2016 | 2015 | Change |  |
| --- | ---: | ---: | ---: | ---: |
| Purchases of property and equipment | $(3,963) | $(2,357) | $(1,606) | (1) |
| Proceeds from sale of assets | 1 | — | 1 |  |
| Intangible asset additions | (219) | (208) | (11) |  |
| Purchases of investment securities | (7,061) | (9,205) | 2,144 |  |
| Proceeds from sale of investment securities | 11,802 | 31,785 | (19,983) | (2) |
| Net cash provided by investing activities | $560 | $20,015 | $(19,455) |  |

(1) Our purchases of property and equipment will vary from period to period based on additional investments needed to support new and existing products and expansion of our manufacturing facilities.

(2) Net proceeds from the sale of our investment securities decreased during the first three months of 2016, as compared to the comparable prior year period, due to certain corporate bonds that had larger investment balances and maturity dates within the first three months ended March 31, 2015.

While we can provide no assurances, we estimate that our capital expenditures in 2016 will approximate $18.0 million to $20.0 million. We anticipate making additional investments in molds, machinery and equipment in our manufacturing operations in the U.S. and Mexico to support new and existing products and in IT to benefit world-wide operations. Additionally, we are in the process of expanding our Mexico manufacturing plant for the anticipated increase in operations as a result of our Slovakian plant closure. We expect to use our cash and investments to fund our capital purchases. These planned amounts of spending are estimates and actual spending may substantially differ from these amounts.

### Cash Flows from Financing Activities

The following table summarizes the changes in our financing cash flows (in thousands):

| Financing Cash Flows: | Three Months Ended March 31, 2016 | 2015 | Change |  |
| --- | ---: | ---: | ---: | ---: |
| Proceeds from exercise of stock options | $5,421 | $4,777 | $644 | (1) |
| Proceeds from employee stock purchase plan | 1,197 | 1,041 | 156 |  |
| Tax benefits from exercise of stock options and vested awards | 2,511 | 3,059 | (548) | (2) |
| Purchase of treasury stock | (16,897) | (1,435) | (15,462) | (3) |
| Net cash (used in) provided by financing activities | $(7,768) | $7,442 | $(15,210) |  |

(1) Proceeds from the exercise of stock options will vary from period to period based on the volume of options exercised and the exercise price of the specific options exercised.

(2) The tax benefit from the exercise of stock options and vested awards will vary from period to period based on the volume of options exercised and awards that vest, the exercise prices of the options exercised and the related stock price at the time the stock activities occur.

(3) During the first three months ended March 31, 2016, we purchased 174,885 shares of our common stock under our share purchase plan on the open market for $15.3 million. Additionally, our employees surrendered 17,528 shares of our common stock from vested restricted stock awards as consideration for approximately $1.5 million in minimum statutory withholding obligations paid on their behalf.

In July 2010, our Board of Directors approved a share purchase plan to purchase up to $40.0 million of our common stock. As of March 31, 2016, we had purchased $32.8 million of our common stock pursuant to this plan, leaving a balance of

$7.2 million available for future purchases. This plan has no expiration date. We may purchase additional shares in future quarters and expect we would use our cash and investments to fund the share purchases.

We have a substantial cash and investment security position generated from profitable operations and stock sales, principally from the exercise of employee stock options. We maintain this position to fund our growth, meet increasing working capital requirements, fund capital expenditures, buy back our common stock on an opportunistic basis and to take advantage of acquisition opportunities that may arise. Our primary investment goal is capital preservation.

As of March 31, 2016, we had $34.1 million of cash and cash equivalents held in local currency by our foreign subsidiaries. If these funds were needed for our operations in the U.S., we would be required to accrue and pay U.S. taxes for a portion of any repatriated funds. However, we expect to permanently reinvest these funds outside of the U.S. and, based on our current plans, we do not presently anticipate a need to repatriate them to fund our U.S. operations.

We believe that our existing cash, cash equivalents and investment securities along with funds expected to be generated from future operations will provide us with sufficient funds to finance our current operations for the next twelve months. In the event that we experience illiquidity in our investment securities, downturns or cyclical fluctuations in our business that are more severe or longer than anticipated or if we fail to achieve anticipated revenue and expense levels, we may need to obtain or seek alternative sources of capital or financing, and we can provide no assurances that the terms of such capital or financing will be available to us on favorable terms, if at all.

### Off Balance Sheet Arrangements

In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification.

### Contractual Obligations

As of March 31, 2016, there were no material changes to our contractual obligations from the amounts reported in our 2015 Form 10-K, except with respect to our purchase obligations as follows (in thousands):

| Contractual Obligations | 2016 |
| --- | ---: |
| Purchase obligations | $5,699 |
|  | $5,699 |

### Critical Accounting Policies

In our Annual Report on Form 10-K for the year ended December 31, 2015, we identified the critical accounting policies which affect our more significant estimates and assumptions used in preparing our consolidated financial statements. We have not changed these policies from those previously disclosed in our Annual Report.

### New Accounting Pronouncements

See Note 4 to Part I, Item 1. Financial Statements.

### Forward Looking Statements

Various portions of this Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis of Financial Condition and Results of Operations, and documents referenced herein, describe trends in our business and finances that we perceive and state some of our expectations and beliefs about our future. These statements about the future are “forward looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we identify them by using words such as "anticipate," "believe," "expect," "estimate," "intend," "plan," "will," "continue," "could," "may," and by similar expressions and statements about aims, goals and plans. The forward looking statements are based on the best information currently available to us and assumptions that we believe are reasonable, but we do not intend the statements to be representations as to future results. They include, without limitation, statements about:

- future growth; future operating results and various elements of operating results, including future expenditures and effects with respect to sales and marketing and product development and acquisition efforts; future sales and unit volumes of products; expected increases and decreases in sales; deferred revenue; accruals for restructuring charges, future license, royalty and revenue share income; production costs; gross margins; litigation expense; future SG&A and R&D expenses; manufacturing expenses; future costs of expanding our business; income; losses; cash flow; amortization; source of funds for capital purchases and operations; future tax rates; alternative sources of capital or financing; changes in working capital items such as receivables and inventory; selling prices; and income taxes;
- factors affecting operating results, such as shipments to specific customers; reduced dependence on current proprietary products; loss of a strategic relationship; change in demand; domestic and international sales; expansion in international markets, selling prices; future increases or decreases in sales of certain products and in certain markets and distribution channels; maintaining strategic relationships and securing long-term and multi-product contracts with large healthcare providers and major buying organizations; increases in systems capabilities; introduction, development and sales of new products; including SwabCap and integration of EXC Holding Corp.; benefits of our products over competing systems; qualification of our new products for the expedited Section 510(k) clearance procedure; possibility of lengthier clearance process for new products; planned increases in marketing; warranty claims; rebates; product returns; bad debt expense; amortization expense; inventory requirements; lives of property and equipment; manufacturing efficiencies and cost savings; unit manufacturing costs; establishment or expansion of production facilities inside or outside of the U. S.; planned new orders for machinery and equipment; adequacy of production capacity; results of R&D; our plans to repurchase shares of our common stock; asset impairment losses; relocation of manufacturing facilities and personnel; effect of expansion of manufacturing facilities on production efficiencies and resolution of production inefficiencies; the effect of costs to customers and delivery times; business seasonality and fluctuations in quarterly results; customer ordering patterns and the effects of new accounting pronouncements; and
- new or extended contracts with manufacturers and buying organizations; dependence on a small number of customers; loss of larger distributors and the ability to locate other distributors; the impact of the Pfizer acquisition of Hospira; future sales to and revenues from Pfizer and the importance of Pfizer to our growth; effect of the current relationship with Pfizer and the settlement with Hospira, including its effect on future revenues and our positioning with respect to new product introductions and market share; growth of our products in future years; design features of Clave products; the outcome of our strategic initiatives; regulatory approvals and compliance; outcome and impact of litigation; patent protection and intellectual property landscape; patent infringement claims and the impact of newly issued patents on other medical devices; competitive and market factors, including continuing development of competing products by other manufacturers; improved production processes and higher volume production; innovation requirements; consolidation of the healthcare provider market and downward pressure on selling prices; distribution or financial capabilities of competitors; healthcare reform legislation; use of treasury stock; working capital requirements; liquidity and realizable value of our investment securities; future investment alternatives; foreign currency denominated financial instruments; foreign exchange risk; commodity price risk; our expectations regarding liquidity and capital resources over the next twelve months; plans to convert existing space; capital expenditures; our planned reinvestment of cash and cash equivalents held by our foreign subsidiaries; acquisitions of other businesses or product lines, indemnification liabilities and contractual liabilities.

Forward-looking statements involve certain risks and uncertainties, which may cause actual results to differ materially from those discussed in each such statement. First, one should consider the factors and risks described in the statements themselves or otherwise discussed herein. Those factors are uncertain, and if one or more of them turn out differently than we currently expect, our operating results may differ materially from our current expectations.

Second, investors should read the forward looking statements in conjunction with the Risk Factors discussed in Part I, Item 1A of our Annual Report on Form 10-K with the SEC for the year ended December 31, 2015 and our other reports and registration statements filed with the SEC. Also, actual future operating results are subject to other important factors and risks that we cannot predict or control, including without limitation, the following:

- general economic and business conditions, both in the U.S. and internationally;
- unexpected changes in our arrangements with Pfizer or our other large customers;
- outcome of litigation;
- fluctuations in foreign exchange rates and other risks of doing business internationally;
- increases in labor costs or competition for skilled workers;
- increases in costs or availability of the raw materials need to manufacture our products;
- the effect of price and safety considerations on the healthcare industry;
- competitive factors, such as product innovation, new technologies, marketing and distribution strength and price erosion;
- the successful development and marketing of new products;
- unanticipated market shifts and trends;
- the impact of legislation affecting government reimbursement of healthcare costs;
- changes by our major customers and independent distributors in their strategies that might affect their efforts to market our products;
- the effects of additional governmental regulations;
- unanticipated production problems; and
- the availability of patent protection and the cost of enforcing and of defending patent claims.

The forward-looking statements in this report are subject to additional risks and uncertainties, including those detailed from time to time in our other filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof and, except as required by law, we undertake no obligation to update or revise any of them, whether as a result of new information, future events or otherwise.

## Market risk

As filed, 2,828 characters.

#### Financial Market Risk

We had a portfolio of government bonds, corporate bonds, U.S. Treasury securities, commercial paper and certificates of deposit of $36.4 million as of March 31, 2016. The securities are all “investment grade”, comprised of $7.2 million of pre-refunded municipal securities, $21.4 million of corporate bonds, $6.0 million of U.S. Treasury securities, $0.7 million of commercial paper and $1.0 million of certificates of deposit. The pre-refunded municipal securities are fully escrowed by U.S. government Treasury bills with low market risk.

Our future earnings are subject to potential increase or decrease because of changes in short-term interest rates. Generally, each one-percentage point change in the discount rate will cause our overall yield to change by two-thirds to three-quarters of a percentage point, depending upon the relative mix of our portfolio and market conditions specific to the securities in which we invest. Two-thirds to three-quarters of a percentage point change in our earnings on investment securities would create a change of approximately $0.3 million to investment income based on the investment securities balance at March 31, 2016.

#### Foreign Exchange Risk

We have foreign currency exchange risk related to foreign-denominated cash, short-term investments, accounts

receivable and accounts payable. In our European operations, our net Euro asset position at March 31, 2016 was

approximately €22.7 million. We also have approximately €69.9 million in Euro denominated cash and investment accounts

held by our corporate entity. A 10% change in the conversion of the Euro to the U.S. dollar for our cash and investments,

accounts receivable, accounts payable and accrued liabilities from the March 31, 2016 spot rate would impact our

consolidated amounts on these balance sheet items by approximately $10.5 million, or 2.6% of these consolidated net assets. We expect that in the future, with the growth of our European distribution operations, net Euro denominated instruments will continue to increase. We currently do not hedge our foreign currency exposures.

Sales from the U.S. to foreign distributors are denominated in U.S. dollars, Euros, South African Rand and Australian dollars. We have manufacturing, sales and distribution facilities in several countries and we conduct business transactions denominated in various foreign currencies, although principally the Euro and Mexican Peso. A 10% change in the conversion of the Mexican Peso to the U.S. dollar from the average exchange rate we experienced in 2016 and our manufacturing spending from 2016 would have impacted 2016 cost of goods sold by approximately $0.6 million. To date, the change in the conversion of the Euro to the U.S. dollar has not had a material impact to our operating earnings.

## Controls and procedures

As filed, 1,077 characters.

#### Disclosure Controls and Procedures

Our principal executive officer and principal financial officer have concluded, based on their evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this Report, that our disclosure controls and procedures are effective to ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure and that such information is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.

There was no change in our internal control over financial reporting during the quarter ended March 31, 2016 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 590 characters.

In evaluating an investment in our common stock, investors should consider carefully, among other things, the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2015, as well as the information contained in this Quarterly Report and our other reports and registration statements filed with the SEC. There have been no material changes in the risk factors as previously disclosed under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K with the SEC for the year ended December 31, 2015.

Filed May 10, 2016.
Source: SEC EDGAR, the filing index for accession 0000883984-16-000063. Last ingested by Listed: Nov 14, 2026, 20:54 ET. No prices; not investment advice.
